BR0110530A - Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina - Google Patents
Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrinaInfo
- Publication number
- BR0110530A BR0110530A BR0110530-2A BR0110530A BR0110530A BR 0110530 A BR0110530 A BR 0110530A BR 0110530 A BR0110530 A BR 0110530A BR 0110530 A BR0110530 A BR 0110530A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- cyclodextrin
- compositions containing
- glycopeptide antibiotic
- disclosed
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"COMPOSIçõES FARMACêUTICAS CONTENDO UM ANTIBIóTICO GLICOPEPTìDICO E UMA CICLODEXTRINA". São reveladas composições farmacêuticas contendo uma ciclodextrina e uma quantidade terapeuticamente eficaz de um antibiótico glicopeptídico ou um sal desse. Também são revelados métodos de tratamento de doenças bacterianas em um mamífero pela administração de tais composições farmacêuticas.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20117800P | 2000-05-02 | 2000-05-02 | |
US21341000P | 2000-06-22 | 2000-06-22 | |
US21342800P | 2000-06-22 | 2000-06-22 | |
US21341700P | 2000-06-22 | 2000-06-22 | |
US21314600P | 2000-06-22 | 2000-06-22 | |
US21341500P | 2000-06-22 | 2000-06-22 | |
US22672700P | 2000-08-18 | 2000-08-18 | |
PCT/US2001/014000 WO2001082971A2 (en) | 2000-05-02 | 2001-05-01 | Cyclodextrin containing glycopeptide antibiotic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0110530A true BR0110530A (pt) | 2003-04-08 |
Family
ID=27569291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0110530-2A BR0110530A (pt) | 2000-05-02 | 2001-05-01 | Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina |
Country Status (12)
Country | Link |
---|---|
US (5) | US6858584B2 (pt) |
EP (1) | EP1278549B1 (pt) |
JP (2) | JP4870314B2 (pt) |
CN (1) | CN1223378C (pt) |
AT (1) | ATE416791T1 (pt) |
AU (1) | AU2001259306A1 (pt) |
BR (1) | BR0110530A (pt) |
CA (2) | CA2408008C (pt) |
DE (1) | DE60136926D1 (pt) |
ES (1) | ES2316445T3 (pt) |
SI (1) | SI1278549T1 (pt) |
WO (1) | WO2001082971A2 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1278549T1 (sl) | 2000-05-02 | 2009-04-30 | Theravance Inc | Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik |
UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
TWI275594B (en) | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
US7499410B2 (en) | 2001-12-26 | 2009-03-03 | Cisco Technology, Inc. | Fibre channel switch that enables end devices in different fabrics to communicate with one another while retaining their unique fibre channel domain—IDs |
US7599360B2 (en) * | 2001-12-26 | 2009-10-06 | Cisco Technology, Inc. | Methods and apparatus for encapsulating a frame for transmission in a storage area network |
GB0206930D0 (en) * | 2002-03-23 | 2002-05-08 | Univ Durham | Method and apparatus for the formation of hydrophobic surfaces |
US7406034B1 (en) | 2002-04-01 | 2008-07-29 | Cisco Technology, Inc. | Methods and apparatus for fibre channel frame delivery |
US7616637B1 (en) | 2002-04-01 | 2009-11-10 | Cisco Technology, Inc. | Label switching in fibre channel networks |
US7206288B2 (en) * | 2002-06-12 | 2007-04-17 | Cisco Technology, Inc. | Methods and apparatus for characterizing a route in fibre channel fabric |
US7433326B2 (en) | 2002-11-27 | 2008-10-07 | Cisco Technology, Inc. | Methods and devices for exchanging peer parameters between network devices |
EP1641480A1 (en) * | 2003-05-27 | 2006-04-05 | Theravance, Inc. | Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent |
TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
CA2579096C (en) * | 2004-09-08 | 2012-11-13 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds |
US7593324B2 (en) * | 2004-10-25 | 2009-09-22 | Cisco Technology, Inc. | Graceful port shutdown protocol for fibre channel interfaces |
US7916628B2 (en) | 2004-11-01 | 2011-03-29 | Cisco Technology, Inc. | Trunking for fabric ports in fibre channel switches and attached devices |
BRPI0516657A (pt) | 2004-11-29 | 2008-09-16 | Univ Nagoya Nat Univ Corp | derivados de monÈmero antibiótico de glicopeptìdeo |
US7649844B2 (en) * | 2004-12-29 | 2010-01-19 | Cisco Technology, Inc. | In-order fibre channel packet delivery |
US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
DE102005056194A1 (de) * | 2005-11-21 | 2007-07-12 | Combinature Biopharm Ag | Neue Lipopeptid Zusammensetzungen |
US7795207B2 (en) | 2005-11-21 | 2010-09-14 | Harald Labischinski | Lipopeptide compositions |
EP1954292B1 (en) * | 2005-11-28 | 2014-05-07 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
MX2010010998A (es) * | 2008-04-07 | 2011-01-25 | Chelsea Therapeutics Inc | Composiciones de antifolato. |
EP2324041A4 (en) | 2008-08-13 | 2012-06-13 | Targanta Therapeutics Corp | PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS |
EP3006038B1 (en) | 2008-08-30 | 2024-07-03 | The Medicines Company | Single doses of oritavancin for treating or preventing a bacterial infection |
CA2760159C (en) | 2009-04-28 | 2021-01-12 | Thomas Parr, Jr. | Methods of treating bacterial infections using oritavancin |
WO2011005832A1 (en) * | 2009-07-08 | 2011-01-13 | Chelsea Therapeutics, Inc. | Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl] -benzoylamino} -4-methylenξ-penta nedioic acid |
EP2496237A2 (en) * | 2009-11-06 | 2012-09-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
US20110237609A1 (en) * | 2010-03-29 | 2011-09-29 | Chelsea Therapeutics, Inc. | Antifolate compositions |
US8658652B2 (en) | 2010-12-07 | 2014-02-25 | Chelsea Therapeutics, Inc. | Antifolate combinations |
CA2904387C (en) | 2013-03-15 | 2021-12-07 | Melinta Therapeutics, Inc. | Methods of treating infections in overweight and obese patients using antibiotics |
PL3038616T3 (pl) | 2013-08-26 | 2023-08-07 | Melinta Therapeutics, Inc. | Metody leczenia bakteriemii i zapalenia kości i szpiku z zastosowaniem orytawancyny |
US9697843B2 (en) * | 2014-04-30 | 2017-07-04 | Qualcomm Incorporated | High band excitation signal generation |
AU2017221435A1 (en) * | 2016-02-18 | 2018-09-06 | Melinta Therapeutics, Inc. | Oritavancin formulations |
US20200171124A1 (en) | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
CN107325159A (zh) * | 2016-04-29 | 2017-11-07 | 中国科学院上海药物研究所 | 一类万古霉素衍生物、其制备方法、药物组合物和用途 |
BR112018072948A2 (pt) | 2016-05-09 | 2019-02-19 | Xellia Pharmaceuticals Aps | composição farmacêutica líquida, e, método para a estabilização de um antibiótico glicopeptídeo em uma solução farmacêutica líquida. |
US11072668B2 (en) | 2017-01-03 | 2021-07-27 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
AU2018247167B2 (en) | 2017-03-28 | 2024-05-16 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
CN107987131B (zh) * | 2017-11-16 | 2021-03-09 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的化合物、其制备方法和应用 |
CN111836648A (zh) | 2018-03-06 | 2020-10-27 | 北卡罗来纳大学查佩尔希尔分校 | 作为可生物降解抗菌支架的一氧化氮释放型环糊精以及其相关方法 |
WO2019238557A1 (en) | 2018-06-13 | 2019-12-19 | Dybly Ag | Preparation of condensed triazepine derivatives and their use as bet inhibitors |
US11421044B2 (en) | 2018-12-28 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
WO2024079223A1 (en) | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US87494A (en) * | 1869-03-02 | William h | ||
US63916A (en) * | 1867-04-16 | Improvement in cotton peess | ||
US229775A (en) * | 1880-07-06 | Eobeet h | ||
US77280A (en) * | 1868-04-28 | John l | ||
US207797A (en) * | 1878-09-10 | Improvement in check-rein hooks | ||
US73371A (en) * | 1868-01-14 | Robert moxley | ||
US4371673A (en) | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
DE3372705D1 (en) | 1982-04-30 | 1987-09-03 | Takeda Chemical Industries Ltd | Pharmaceutical composition and its use |
DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
US4639433A (en) * | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
EP0335545B2 (en) | 1988-03-29 | 1998-09-23 | University Of Florida | Pharmaceutical formulations for parenteral use |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
CA2031803C (en) | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
KR100212162B1 (ko) | 1990-06-15 | 1999-08-02 | 루시에 라포인테-쇼우, 카르타 커티 케이 | 히루딘의 아미노산 시퀸스를 기재로 한 트롬빈 억제제 |
US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
EP0610295A1 (en) * | 1991-10-16 | 1994-08-17 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
IT1251751B (it) * | 1991-10-31 | 1995-05-23 | Sclavo Ricerca S R L | Metodo per la coltura di microrganismi dei generi helicobacter, campylobacter e arcobacter, utilizzando terreni di coltura contenenti ciclodestrine o metil-cellulosa o loro miscele |
US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
AU672862B2 (en) * | 1992-12-02 | 1996-10-17 | Insite Vision Incorporated | Cyclodextrin and polymer based drug delivery system |
CA2134753A1 (en) | 1993-03-08 | 1994-09-15 | Peter K. Chiang | Cyclodextrin-peptide compositions |
CA2156719A1 (en) | 1993-03-12 | 1994-09-15 | Ramesh Prakash | Recombinant epstein-barr virus protein and its use in vaccine |
AU7935494A (en) | 1993-10-25 | 1995-05-22 | National Research Council Of Canada | Bivalent thrombin inhibitors |
US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
TW457248B (en) | 1994-01-28 | 2001-10-01 | Lilly Co Eli | Glycopeptide antibiotic derivatives |
SE510830C2 (sv) * | 1995-02-16 | 1999-06-28 | Pure Pulse Technologies Inc | Sätt att med god hållbarhet förpacka färskt kött i en förpackning av plast |
US5919756A (en) | 1996-06-28 | 1999-07-06 | Eli Lilly And Company | Amides |
ATE252369T1 (de) | 1996-08-09 | 2003-11-15 | Alcon Mfg Ltd | Konservierungssysteme fur cyclodextrine enthaltende arzneimittel |
US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
US5916873A (en) | 1997-04-17 | 1999-06-29 | Eli Lilly And Company | Teicoplanin derivatives |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
DK0889056T3 (da) * | 1997-07-01 | 2006-07-17 | Pfizer Prod Inc | Process for making a cyclodextrin |
GB2344713B (en) * | 1998-02-10 | 2003-05-07 | Furuno Electric Co | Display system |
SI1140993T1 (en) * | 1998-12-23 | 2003-12-31 | Theravance, Inc. | Glycopeptide derivatives and pharmaceutical compositions containing the same |
JP2003512017A (ja) | 1998-12-23 | 2003-04-02 | アベンティス、パストゥール、リミテッド | クラミジア抗原および対応するdna断片ならびにその使用 |
DE19911097A1 (de) | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
US6518243B1 (en) | 1999-04-02 | 2003-02-11 | Trustees Of Princeton University | Desleucyl glycopeptide antibiotics and methods of making same |
WO2001083520A2 (en) * | 2000-05-02 | 2001-11-08 | Theravance,Inc | Polyacid glycopeptide derivatives |
SI1278549T1 (sl) | 2000-05-02 | 2009-04-30 | Theravance Inc | Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik |
PL218223B1 (pl) * | 2000-06-21 | 2014-10-31 | Cubist Pharmaceuticals | Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny |
US6872804B2 (en) * | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
AU2001259302A1 (en) | 2000-06-22 | 2002-01-02 | Yongqi Mu | Glycopeptide disulfide and thioester derivatives |
UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
WO2001098329A1 (en) * | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
AU2001259303A1 (en) * | 2000-06-22 | 2002-01-02 | Advanced Medicine, Inc. | Glycopeptide carboxy-saccharide derivatives |
US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
US9216185B2 (en) * | 2008-07-11 | 2015-12-22 | Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon | Use of cilastatin to reduce nephrotatoxicity of various compounds |
-
2001
- 2001-05-01 SI SI200130903T patent/SI1278549T1/sl unknown
- 2001-05-01 AU AU2001259306A patent/AU2001259306A1/en not_active Abandoned
- 2001-05-01 JP JP2001579844A patent/JP4870314B2/ja not_active Expired - Lifetime
- 2001-05-01 BR BR0110530-2A patent/BR0110530A/pt not_active Application Discontinuation
- 2001-05-01 AT AT01932810T patent/ATE416791T1/de not_active IP Right Cessation
- 2001-05-01 US US09/846,893 patent/US6858584B2/en not_active Expired - Lifetime
- 2001-05-01 WO PCT/US2001/014000 patent/WO2001082971A2/en active Application Filing
- 2001-05-01 CA CA2408008A patent/CA2408008C/en not_active Expired - Lifetime
- 2001-05-01 CA CA2726789A patent/CA2726789A1/en not_active Abandoned
- 2001-05-01 EP EP01932810A patent/EP1278549B1/en not_active Expired - Lifetime
- 2001-05-01 CN CNB018104746A patent/CN1223378C/zh not_active Expired - Lifetime
- 2001-05-01 ES ES01932810T patent/ES2316445T3/es not_active Expired - Lifetime
- 2001-05-01 DE DE60136926T patent/DE60136926D1/de not_active Expired - Lifetime
-
2004
- 2004-08-31 US US10/930,585 patent/US7026288B2/en not_active Expired - Lifetime
- 2004-08-31 US US10/931,122 patent/US7067483B2/en not_active Expired - Lifetime
-
2006
- 2006-04-25 US US11/410,597 patent/US7544364B2/en not_active Expired - Lifetime
-
2008
- 2008-04-03 JP JP2008097622A patent/JP2008231109A/ja active Pending
-
2009
- 2009-04-29 US US12/431,940 patent/US8158580B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE416791T1 (de) | 2008-12-15 |
US6858584B2 (en) | 2005-02-22 |
EP1278549A2 (en) | 2003-01-29 |
CA2726789A1 (en) | 2001-11-08 |
AU2001259306A1 (en) | 2001-11-12 |
CN1223378C (zh) | 2005-10-19 |
US7067483B2 (en) | 2006-06-27 |
US20020077280A1 (en) | 2002-06-20 |
SI1278549T1 (sl) | 2009-04-30 |
JP2008231109A (ja) | 2008-10-02 |
EP1278549B1 (en) | 2008-12-10 |
DE60136926D1 (de) | 2009-01-22 |
CA2408008A1 (en) | 2001-11-08 |
WO2001082971A3 (en) | 2002-05-23 |
WO2001082971A2 (en) | 2001-11-08 |
US8158580B2 (en) | 2012-04-17 |
CA2408008C (en) | 2011-01-18 |
JP4870314B2 (ja) | 2012-02-08 |
US20050032676A1 (en) | 2005-02-10 |
US7026288B2 (en) | 2006-04-11 |
US20050026820A1 (en) | 2005-02-03 |
JP2003531869A (ja) | 2003-10-28 |
CN1441680A (zh) | 2003-09-10 |
US20100081609A1 (en) | 2010-04-01 |
US20060194717A1 (en) | 2006-08-31 |
US7544364B2 (en) | 2009-06-09 |
ES2316445T3 (es) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0110530A (pt) | Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina | |
DK1169060T3 (da) | Natriumkanalblokkerpræparater og anvendelse deraf | |
SG153833A1 (en) | Methods of treatment of endobronchial infections | |
CY1107467T1 (el) | Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων | |
PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
AR034343A1 (es) | Combinaciones farmaceuticas | |
ATE388153T1 (de) | Quervernetzte glycopeptid-cephalosporin- antibiotika | |
AP2001002142A0 (en) | 13-membered azalides and their use as antibiotic agents. | |
SV2002000235A (es) | Composiciones farmaceuticas que comprenden valdecoxib | |
ATE450540T1 (de) | Quervernetzte glycopeptid-cephalosporin- antibiotika | |
ATE314376T1 (de) | Kreuzverquerte glycopeptid-cephalosporin- antibiotika | |
HUP0004282A2 (hu) | 2-Halogén-6-0-szubsztituált ketolidszármazékok | |
ATE556088T1 (de) | Konjugat beinhaltend cephalosporin und glykopeptidantibiotikum | |
BR0002577A (pt) | Suspensões orais de trovafloxacina | |
BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
ATE376557T1 (de) | Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika | |
ATE350064T1 (de) | Pharmazeutische zusammensetzungen von rapamycines | |
DK1181300T3 (da) | 6-O-carbamatketolidderivater | |
SE0004827D0 (sv) | Therapeutic compounds | |
AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 | |
WO2002057281A3 (en) | Aminoglycosides as antibiotics | |
ATE320820T1 (de) | Pharmazeutische zusammensetzungen von antibiotika und fruktan-gemische |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: B82Y 5/00 (2011.01), A61K 9/00 (2006.01), A61K 9/0 |